Zehender, Ariella
Li, Yi-Nan http://orcid.org/0000-0001-8934-9361
Lin, Neng-Yu
Stefanica, Adrian
Nüchel, Julian http://orcid.org/0000-0002-8126-415X
Chen, Chih-Wei
Hsu, Hsiao-Han
Zhu, Honglin
Ding, Xiao
Huang, Jingang
Shen, Lichong
Györfi, Andrea-Hermina http://orcid.org/0000-0002-4960-3369
Soare, Alina
Rauber, Simon http://orcid.org/0000-0001-8306-9334
Bergmann, Christina
Ramming, Andreas
Plomann, Markus http://orcid.org/0000-0001-6509-5627
Eckes, Beate http://orcid.org/0000-0002-0936-0702
Schett, Georg http://orcid.org/0000-0001-8740-9615
Distler, Jörg H. W. http://orcid.org/0000-0001-7408-9333
Article History
Received: 23 September 2019
Accepted: 29 April 2021
First Online: 20 July 2021
Competing interests
: Although none of the authors has any direct conflict of interest related to autophagy in fibrosis, J.H.W.D. are involved in the development of targeted therapies for fibrotic diseases such as SSc. J.H.W.D. has consultancy relationships with Actelion, Active Biotech, Anamar, ARXX, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi and UCB. J.H.W.D. has received research funding from Anamar, Active Biotech, Array Biopharma, aTyr, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Novartis, Sanofi-Aventis, RedX, UCB. J.H.W.D. is stock owner of 4D Science and Scientific head of FibroCure. The remaining authors declare no competing interests.